Cargando…

Medical Cannabis for Intractable Epilepsy in Childhood: A Review

In recent years, cannabis has been gaining increasing interest in both the medical research and clinical fields, with regard to its therapeutic effects in various disorders. One of the major fields of interest is its role as an anticonvulsant for refractory epilepsy, especially in the pediatric popu...

Descripción completa

Detalles Bibliográficos
Autor principal: Ben-Zeev, Bruria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rambam Health Care Campus 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000162/
https://www.ncbi.nlm.nih.gov/pubmed/32017679
http://dx.doi.org/10.5041/RMMJ.10387
_version_ 1783493991242661888
author Ben-Zeev, Bruria
author_facet Ben-Zeev, Bruria
author_sort Ben-Zeev, Bruria
collection PubMed
description In recent years, cannabis has been gaining increasing interest in both the medical research and clinical fields, with regard to its therapeutic effects in various disorders. One of the major fields of interest is its role as an anticonvulsant for refractory epilepsy, especially in the pediatric population. This paper presents and discusses the current accumulated knowledge regarding artisanal cannabis and Epidiolex®, a United States Food and Drug Administration (FDA)-approved pure cannabidiol (CBD), in epilepsy management in pediatrics, by reviewing the literature and raising debate regarding further research directions.
format Online
Article
Text
id pubmed-7000162
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Rambam Health Care Campus
record_format MEDLINE/PubMed
spelling pubmed-70001622020-02-24 Medical Cannabis for Intractable Epilepsy in Childhood: A Review Ben-Zeev, Bruria Rambam Maimonides Med J Special Issue on Cannabis in Medicine In recent years, cannabis has been gaining increasing interest in both the medical research and clinical fields, with regard to its therapeutic effects in various disorders. One of the major fields of interest is its role as an anticonvulsant for refractory epilepsy, especially in the pediatric population. This paper presents and discusses the current accumulated knowledge regarding artisanal cannabis and Epidiolex®, a United States Food and Drug Administration (FDA)-approved pure cannabidiol (CBD), in epilepsy management in pediatrics, by reviewing the literature and raising debate regarding further research directions. Rambam Health Care Campus 2020-01-30 /pmc/articles/PMC7000162/ /pubmed/32017679 http://dx.doi.org/10.5041/RMMJ.10387 Text en Copyright: © 2020 Bruria Ben-Zeev This is an open-access article. All its content, except where otherwise noted, is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Special Issue on Cannabis in Medicine
Ben-Zeev, Bruria
Medical Cannabis for Intractable Epilepsy in Childhood: A Review
title Medical Cannabis for Intractable Epilepsy in Childhood: A Review
title_full Medical Cannabis for Intractable Epilepsy in Childhood: A Review
title_fullStr Medical Cannabis for Intractable Epilepsy in Childhood: A Review
title_full_unstemmed Medical Cannabis for Intractable Epilepsy in Childhood: A Review
title_short Medical Cannabis for Intractable Epilepsy in Childhood: A Review
title_sort medical cannabis for intractable epilepsy in childhood: a review
topic Special Issue on Cannabis in Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000162/
https://www.ncbi.nlm.nih.gov/pubmed/32017679
http://dx.doi.org/10.5041/RMMJ.10387
work_keys_str_mv AT benzeevbruria medicalcannabisforintractableepilepsyinchildhoodareview